Cyril BOUR

De Azevedo, J., Mourtada, J., Bour, C., Devignot, V., Schultz, P., Borel, C., Pencreach, E., Mellitzer, G., Gaiddon, C., & Jung, A. C. (2022). The EXTREME Regimen Associating Cetuximab and Cisplatin Favors Head and Neck Cancer Cell Death and Immunogenicity with the Induction of an Anti-Cancer Immune Response. Cells, 11(18), 2866. https://doi.org/10.3390/cells11182866

Reita, D., Bour, C., Benbrika, R., Groh, A., Pencreach, E., Guérin, E., & Guenot, D. (2019). Synergistic Anti-Tumor Effect of mTOR Inhibitors with Irinotecan on Colon Cancer Cells. Cancers, 11(10). https://doi.org/10.3390/cancers11101581

Job, S., Reyniès, A. de, Heller, B., Weiss, A., Guérin, E., Macabre, C., Ledrappier, S., Bour, C., Wasylyk, C., Etienne-Selloum, N., Brino, L., Gaiddon, C., Wasylyk, B., & Jung, A. C. (2019). Preferential Response of Basal-Like Head and Neck Squamous Cell Carcinoma Cell Lines to EGFR-Targeted Therapy Depending on EREG-Driven Oncogenic Addiction. Cancers, 11(6). https://doi.org/10.3390/cancers11060795

Romain, B., Benbrika-Nehmar, R., Marisa, L., Legrain, M., Lobstein, V., Oravecz, A., Poidevin, L., Bour, C., Freund, J.-N., Duluc, I., Guenot, D., & Pencreach, E. (2017). Histone hypoacetylation contributes to CXCL12 downregulation in colon cancer: impact on tumor growth and cell migration. Oncotarget, 8(24), 38351–38366. https://doi.org/10.18632/oncotarget.16323